NCT01545336已完成2 期
A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 3
- 主要终点
- Tricuspid Annular Plane Systolic Excursion (TAPSE)
研究概览
简要总结
The main purpose of this clinical trial is to study the safety and efficacy of anastrozole in adults diagnosed with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated. The study will also evaluate if anastrozole effects estradiol (E2) hormone levels, a sex hormone, and improves the function of the lower right chamber of the heart (right ventricle).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous documentation of mean pulmonary artery pressure > 25 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) < 16 mm Hg and PVR > 3 WU at any time before study entry.
- •Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection.
- •Most recent pulmonary function tests with FEV1/FVC >50% AND either a) total lung capacity > 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest
- •Ability to perform six minute walk testing without limitations in musculoskeletal function or coordination.
- •If female, post-menopausal state, defined as:
- •> 50 years old AND
- •a) have not menstruated during the preceding 12 months OR
- •b) have follicle-stimulating hormone (FSH) levels (> 40 IU/L) OR
- •< 50 years and FSH (> 40 IU/L) OR
- •having had a bilateral oophorectomy
- •Informed consent
排除标准
- •Treatment with estrogen or anti-hormone therapy (tamoxifen, fulvestrant, etc.)
- •WHO Class IV functional status
- •History of breast cancer
- •Clinically significant untreated sleep apnea
- •Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on echocardiography
- •Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors) within three months of enrollment; the dose must be stable for at least 3 months prior to Baseline Visit
- •Hormone therapy
- •Hospitalized or acutely ill
- •Renal failure (creatinine > 2.0)
- •Child-Pugh Class C cirrhosis
- •Current or recent (< 6 months) chronic heavy alcohol consumption
- •Current use of another investigational drug (non-FDA approved) for PAH
- •Enrollment in a clinical trial within one month of screening
- •Age < 18
研究组 & 干预措施
Anastrozole
Experimental
1 mg tablet by mouth once daily for 3 months
干预措施: Anastrozole (Drug)
Placebo
Placebo Comparator
Placebo tablet by mouth once daily for 3 months
干预措施: Placebo (Drug)
结局指标
主要结局
Tricuspid Annular Plane Systolic Excursion (TAPSE)
时间窗: Baseline, 3 months
Plasma Estradiol (E2) Level
时间窗: Baseline, 3 months
次要结局
- Six Minute Walk Distance(Baseline, 3 months)
研究者
研究点 (3)
Loading locations...
相似试验
终止
2 期
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's DiseaseAlzheimer's DiseaseNCT00299988Weill Medical College of Cornell University24
已完成
2 期
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaNCT05368285Celldex Therapeutics208
进行中（未招募）
3 期
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)Epidermolysis BullosaNCT05838092RHEACELL GmbH & Co. KG9
进行中（未招募）
3 期
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)Epidermolysis BullosaNCT05464381RHEACELL GmbH & Co. KG91
已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic FibrosisNCT03911713Vertex Pharmaceuticals Incorporated77